AURA AURA BIOSCIENCES INC Product Launches 8-K Filing 2024 - Positive Study Results Aura Biosciences, Inc. announced positive Phase 2 study results for its drug bel-sar in treating early-stage choroidal melanoma, presented at a conference in Lisbon on September 12, 2024.Get access to all SEC 8-K filings of the AURA BIOSCIENCES INC